122 related articles for article (PubMed ID: 34083279)
1. The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells.
Kim SY; Jeong EH; Lee TG; Kim HR; Kim CH
Anticancer Res; 2021 Jun; 41(6):2885-2894. PubMed ID: 34083279
[TBL] [Abstract][Full Text] [Related]
2. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
3. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
[No Abstract] [Full Text] [Related]
4. Rapamycin and trametinib: a rational combination for treatment of NSCLC.
Sun CY; Li YZ; Cao D; Zhou YF; Zhang MY; Wang HY
Int J Biol Sci; 2021; 17(12):3211-3223. PubMed ID: 34421360
[TBL] [Abstract][Full Text] [Related]
5. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
6. Combined mTOR/MEK inhibition prevents proliferation and induces apoptosis in NF2-mutant tumors.
Li N; Lu XY; Shi WY; Mao FJ; Yang XY; Luo YB; Li W
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5874-5883. PubMed ID: 31298338
[TBL] [Abstract][Full Text] [Related]
7. Effect of rapamycin, an mTOR inhibitor, on radiation sensitivity of lung cancer cells having different p53 gene status.
Nagata Y; Takahashi A; Ohnishi K; Ota I; Ohnishi T; Tojo T; Taniguchi S
Int J Oncol; 2010 Oct; 37(4):1001-10. PubMed ID: 20811722
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells.
Ohara T; Takaoka M; Toyooka S; Tomono Y; Nishikawa T; Shirakawa Y; Yamatsuji T; Tanaka N; Fujiwara T; Naomoto Y
Cancer Sci; 2011 Jul; 102(7):1344-9. PubMed ID: 21521416
[TBL] [Abstract][Full Text] [Related]
9. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
10. RAD001 enhances the radiosensitivity of SCC4 oral cancer cells by inducing cell cycle arrest at the G2/M checkpoint.
Yu CC; Hung SK; Liao HF; Lee CC; Lin HY; Lai HC; Li SC; Ho HC; Huang HB; Su YC
Anticancer Res; 2014 Jun; 34(6):2927-35. PubMed ID: 24922656
[TBL] [Abstract][Full Text] [Related]
11. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus.
Liu D; Xing J; Trink B; Xing M
Int J Cancer; 2010 Dec; 127(12):2965-73. PubMed ID: 21351275
[TBL] [Abstract][Full Text] [Related]
12. Radio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions.
Ushijima H; Suzuki Y; Oike T; Komachi M; Yoshimoto Y; Ando K; Okonogi N; Sato H; Noda SE; Saito J; Nakano T
J Radiat Res; 2015 Jul; 56(4):663-8. PubMed ID: 25887043
[TBL] [Abstract][Full Text] [Related]
13. Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model.
Kim KW; Moretti L; Mitchell LR; Jung DK; Lu B
Clin Cancer Res; 2009 Oct; 15(19):6096-105. PubMed ID: 19773376
[TBL] [Abstract][Full Text] [Related]
14. Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence.
Schick U; Kyula J; Barker H; Patel R; Zaidi S; Gregory C; Hafsi H; Roulstone V; Deutsch E; McLaughlin M; Harrington K
Radiother Oncol; 2015 Nov; 117(2):364-75. PubMed ID: 26163092
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of trametinib to inhibit the mutagenesis by inactivating the protein kinase pathway in non-small cell lung cancer.
Jeanson A; Boyer A; Greillier L; Tomasini P; Barlesi F
Expert Rev Anticancer Ther; 2019 Jan; 19(1):11-17. PubMed ID: 30513023
[No Abstract] [Full Text] [Related]
16. Attenuation of the DNA damage response by transforming growth factor-beta inhibitors enhances radiation sensitivity of non-small-cell lung cancer cells in vitro and in vivo.
Du S; Bouquet S; Lo CH; Pellicciotta I; Bolourchi S; Parry R; Barcellos-Hoff MH
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):91-9. PubMed ID: 25835621
[TBL] [Abstract][Full Text] [Related]
17. AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.
Raghavan P; Tumati V; Yu L; Chan N; Tomimatsu N; Burma S; Bristow RG; Saha D
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e507-14. PubMed ID: 22795803
[TBL] [Abstract][Full Text] [Related]
18. A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancers.
Yamaguchi K; Iglesias-Bartolomé R; Wang Z; Callejas-Valera JL; Amornphimoltham P; Molinolo AA; Cohen EE; Califano JA; Lippman SM; Luo J; Gutkind JS
Oncotarget; 2016 Mar; 7(10):10696-709. PubMed ID: 26882569
[TBL] [Abstract][Full Text] [Related]
19. Sensitization to gamma-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells.
Zhang F; Zhang T; Teng ZH; Zhang R; Wang JB; Mei QB
Cancer Biol Ther; 2009 May; 8(9):823-31. PubMed ID: 19270532
[TBL] [Abstract][Full Text] [Related]
20. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
Sato H; Yamamoto H; Sakaguchi M; Shien K; Tomida S; Shien T; Ikeda H; Hatono M; Torigoe H; Namba K; Yoshioka T; Kurihara E; Ogoshi Y; Takahashi Y; Soh J; Toyooka S
Cancer Sci; 2018 Oct; 109(10):3183-3196. PubMed ID: 30098066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
